Targeting cancer testis antigens in synovial sarcoma

Geoffrey Mitchell,1 Seth M Pollack,2,3,4 Michael J Wagner2,3

ABSTRACT
Synovial sarcoma (SS) is a rare cancer that disproportionately affects children and young adults. Cancer testis antigens (CTAs) are proteins that are expressed early in embryonic development, but generally not expressed in normal tissue. They are aberrantly expressed in many different cancer types and are an attractive therapeutic target for immunotherapies. CTAs are expressed at high levels in SS. This high level of CTA expression makes SS an ideal cancer for treatment strategies aimed at harnessing the immune system to recognize aberrant CTA expression and fight against the cancer. Pivotal clinical trials are now underway, with the potential to dramatically alter the landscape of SS management and treatment from current standards of care. In this review, we describe the rationale for targeting CTAs in SS with a focus on NY-ESO-1 and MAGE-A4, the current state of vaccine and T-cell receptor-based therapies, and consider emerging opportunities for future development.

INTRODUCTION
Synovial sarcoma
Synovial sarcoma (SS) is a rare cancer that comprises between 5%–10% of all soft tissue sarcomas that disproportionately affects children and young adults, with the peak incidence between 15–29 years old, though it can occur at any age.1-3 Although it was originally thought to derive from synovium when first described over 100 years ago,4 SS can develop from any serosal surface including the pleura or sac around the kidney. One hypothesis regarding its cell of origin is that it derives from Myogenic factor 5 expressing multipotent mesenchymal progenitors such as periosteal cells and pre-osteoblasts influenced by paracrine secretion of osteoprotegerin by bone, suggesting why SS often form immediately adjacent to bone.5 Morphologically, SS can present in two distinct histological subtypes: monophasic, which is composed uniformly of spindle cells or biphasic, which contains areas with epithelioid differentiation.

Patients with localized disease are treated with curative intent with surgical resection and radiation therapy. Anthracycline-based chemotherapy is often used in the curative setting and is the primary treatment used in the metastatic setting. Regardless of presentation, 5-year and 10-year overall survival (OS) is 61% and 42%, respectively.1 While patients with localized disease can be cured, patients with disease that has recurred or who have metastatic disease have far worse outcomes. The use of ifosfamide,6 pazopanib,7 and trabectedin8 have improved outcomes for anthracycline refractory patients but profession-free survival with any of these drugs can be measured on the order of months. In spite of great progress with multiple new drugs developed over the past decade, median OS for patients receiving systemic therapy is around 2 years.9

SS is characterized by one of several t(X;18) translocations that is the pathognomonic driver for the tumor and leads to expression of an abnormal SS18-SSX (previously SYT-SSX) fusion protein.10 Recent insights into the mechanism of the SS18-SSX fusions have led to a better understanding of the biology of SS and highlighted the role of chromatin remodeling in SS pathogenesis. SS18 is a normal component of barrier-to-autointegration factor (BAF)-type Switch/Sucrose Non-fermentable (SWI/SNF) complexes.11 SS18-SSX fusions interact with transducin-like enhancer protein 1 and activating transcription factor 2 (ATF2) leading to repression of ATF2 target genes.12 The fusion protein ejects the SMARCB1 (BAF47, INI1) subunit from the BAF complex and leads to altered transcription of genes including HOXC10, BCL2, PAX7, and SOX2, ultimately leading to cancer cell survival.13-16

As described below, SS highly expresses cancer testis antigens (CTAs). Although the mechanisms by which CTAs are expressed in cancer are not clear, epigenetic dysregulation mediated by SS18-SSX fusion proteins may play a key role.

CTAs
It has long been recognized that tumors can elicit immune responses. Early efforts to identify tumor associated antigens in a murine model revealed four antigens that
CTAs in SS
In contrast to most other cancer types, CTA expression in SS is exceptionally high. Additionally, CTA expression in SS is homogenous. Few cancer types, with the exception of myxoid/round cell liposarcoma, demonstrate this unique pattern of CTA expression. Table 1 highlights specific studies that have quantified the expression of CTAs that have been found in SS. Of note, although RT-PCR was used to identify CTA expression in the past, transcript expression does not always correlate with protein expression and immunohistochemistry (IHC) is now the gold standard. The expression of CTAs in SS is a dynamic process with some patients potentially showing expression later in the disease course compared with others. With this in mind, care must be taken when determining the eligibility of patients for CTA-targeted treatments. As the CTAs that have been best characterized in SS, we focus mostly on NY-ESO-1 and MAGE-A4 in this review.

NY-ESO-1 is perhaps the best characterized CTA in SS. While the normal function of the protein is unknown, NY-ESO-1 has been shown to interact with MAGE-C1 and may be important in tumor cell proliferation and tumor survival by inhibition of p53. There have been multiple studies that have confirmed the presence and incidence of NY-ESO-1 in SS with ranges from 49% to 82% with IHC, as well as historically with PCR and microarray. Estimates on the lower end of the spectrum may be underestimating the true incidence of NY-ESO-1 expression by assessing limited amounts of tumor in a tissue microarray. Although NY-ESO-1 expression tends to be heterogenous on most tumor types and can be heterogenous on SS, it is often homogenously expressed in SS. This homogenous expression makes SS an exceptional candidate for NY-ESO-1 targeted therapies.

The MAGE-A family of CTAs consists of MAGE-A, MAGE-B, and MAGE-C. Each of these then have subfamilies and are numbered accordingly. The MAGE-A family directly inhibits the function of p53 by binding to the DNA binding portion of p53. It also leads to increased levels of MDM4, a p53 inhibitor. MAGE-A4 is a CTA that has been shown to be expressed in 53%–82% of SS by IHC. MAGE-A4 is the most relevant of the MAGE family genes for SS. NY-ESO-1 and MAGE-A4 are often expressed in the same tumor, but the two can be expressed independent from one another as well.

Preferentially Expressed Antigen In Melanoma (PRAME) expression has been detected in 86%–100% of SS, though IHC assays for PRAME are not as reliable as those for NY-ESO-1 or MAGE-A4. PRAME aids in tumor survival by inhibiting apoptosis, proliferation arrest, and retinoic acid induced differentiation in two ways. PRAME can bind to the retinoic acid receptor directly or can complex with the polycomb group protein EZH2 to suppress retinoic acid receptor signaling. Importantly, T-cell responses against PRAME have been characterized in other tumor types. Up to this point there are no clinical studies of T cells being used to target PRAME in SS. There are currently two separate ongoing trials (NCT04262466 and NCT03686124) using T-cell receptors (TCRs) to target PRAME positive solid cancers.

The related SSX genes SSX1 and SSX2, the fusion partners defining the SS18-SSX SS translocation, have long been considered CTAs due to their expression being solely in the male testis and location on the X chromosome. The presence of SSX1 and SSX2 in the pathogenic fusion protein in SS makes SSX a potential target for both vaccines and modified T cells.
TARGETING CTAS IN SS

Interventional trials targeting CTAs in SS are summarized in Table 2.

CTA-targeted vaccines

LV305 was a vaccine that targets dendritic cells and induces the expression of NY-ESO-1 to then stimulate T-cell

**Table 1**  Cancer testis antigen (CTA) expression in synovial sarcoma (SS)

| Author | CTA (type) | Method of CTA assessment | Incidence in SS (%) |
|--------|------------|--------------------------|---------------------|
| Kakimoto *et al* | NY-ESO-1 | IHC | 59 |
| Endo *et al* | MAGE-A4 | | 53 |
| Lai *et al* | NY-ESO-1 | | 49 |
| Sellner *et al* | NY-ESO-1 | PCR and IHC | 60 strong + 10 weakly positive |
| Ayyoub *et al* | NY-ESO-1 | PCR and IHC | 100 (n=2) |
| Jungbluth *et al* | NY-ESO-1 | IHC | 80 |
| | MAGE-A4 | | 16 |
| | MAGE-A1 | | 100 |
| | CT7 (MAGEC1) | | 8 |
| Iura *et al* | NY-ESO-1 | PCR and IHC | 61 |
| | MAGE-A4 | | 82 |
| | MAGE-A1 | | 15 |
| | PRAME | | 86 |
| Antonescu *et al* | MAGE-A (unspecified subfamily) | IHC | 88 |
| Jungbluth *et al* | PRAME | IHC | 100 |
| Luk *et al* | PRAME | PCR | 100 |
| Roszik *et al* | PRAME | Cancer Genome Atlas and Cancer Cell Line Encyclopedia | 100 |
| Segal *et al* | NY-ESO-1 | Microarray | 80 |
| | PRAME | | 100 |
| Guillou *et al* | SYT-SSX | RT-PCR | 96 and 100 (monophasic and biphasic) |
| Wei *et al* | SYT-SSX | RT-PCR | 89 |

IHC, immunohistochemistry; PRAME, Preferentially Expressed Antigen In Melanoma.

**Table 2**  Interventional studies of CTA-targeted therapeutics in synovial sarcoma, grouped by therapy type

| Author | Therapy type | Therapy | CTA target | Response |
|--------|--------------|---------|------------|----------|
| Chawla *et al* | Vaccine | CMB305 (LV305+G305) | NY-ESO-1 | No change in OS. |
| Somaiah *et al* | Vaccine | LV305 | NY-ESO-1 | 1/13 patients with PR, 6/13 having SD. |
| Ishihara *et al* | Vaccine | CHP-NYESO-MIS416 | NY-ESO-1 | 1/4 had SD with rest having PD. |
| Kawaguchi *et al* | Vaccine | SYT-SSX | SYT-SSX | 6/12 patients in protocol B had SD. |
| Butler *et al* | TCR | TBI-1301 | NY-ESO-1 | 2/9 patients had PR and 5/9 had SD. |
| Robbins *et al* | TCR | 1G4-α95:LY | NY-ESO-1 | 11/18 patients had PR. |
| D’Angelo *et al* | TCR | NY-ESO-1c259 (SPEAR T Cell) | NY-ESO-1 | 6/12 patients had PR. |
| Ramachandran *et al* | TCR | NY-ESO-1c259 (SPEAR T Cell) | NY-ESO-1 | Had three cohorts for 30 total patients and only 2/30 had PD. |
| Hong *et al* | TCR | ADP-A2M4 | MAGE-A4 | In cohort 3 (N=28) all seven PR were from SS patients. |
| Morgan *et al* | TCR | TCR (unnamed) | MAGE-A3 | Only 1 SS patient. Patient experienced PR. |

CTA, cancer testis antigen; OS, overall survival; PD, progressive disease; PR, positive response; SD, stable disease; SS, synovial sarcoma; TCR, T-cell receptor.
mediated immune response. Initial results of LV305 in a phase 1 trial found that 62% of patients had stable disease as their best response with one patient (4%) having a complete response. Patients with increased clonal expansion of anti-NY-ESO-1 T cells induced by LV305 were also shown to have a significantly longer OS. Efforts to improve the efficacy of LV305 were undertaken with a modified version of LV305, called CMB305. CMB305 includes LV305 boosted with an NY-ESO-1 recombinant protein plus glucopyranosyl lipid A, a TLR-4 agonist, in a stable emulsion (GLA-SE). In an initial Phase 1 trial, CMB305 was safe and elicited antibody responses against NY-ESO-1 in 62.9% of patients and T-cell responses in 47.4%; 22.8% of patients had both. A randomized Phase 2 study with the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with or without CMB305 showed no statistically significant differences between the groups in OS and progression free survival (PFS), and no further study is planned with this vaccine regimen.

CHP-NY-ESO-MIS416 is a vaccine which is a polysaccharide-ligated to NY-ESO-1 used to stimulate MHC I and 2 with a T cell stimulator (MIS416), with NOD2 and TLR9 added as stimulants. In a study of this vaccine across multiple cancer types, only one out of a total of four patients with SS had stable disease (SD) with the rest having progressive disease (PD) as best response. While this was a small cohort all four patients with SS developed a specific immune response as assessed by the presence of NY-ESO-1 specific antibodies. An additional mouse model using the CHP-NY-ESO-MIS426 vaccine in conjunction with an anti-programmed cell death protein 1 (PD1) inhibitor showed a significant decrease in tumor volume, suggesting that co-administration of this vaccine and PD1 inhibitors may be an effective treatment strategy.

Vaccine therapies have also had their own difficulties. The induction of CD8+ lymphocytes can take up to several months to occur and limits the population of patients who can use this method of therapy. Due to the aggressive nature of SS, the utility of a vaccine-based therapy in patients with rapidly progressing disease is limited. Efforts to increase the efficacy of vaccines have used checkpoint inhibitors, synthetic TLR4, and Freund’s adjuvant to increase and boost the cytotoxicity of the stimulated T cells. In addition to stimulating humoral immunity, vaccination with NY-ESO-1 vaccine in metastatic melanoma also triggered an increase in regulatory T-cells that recognize NY-ESO-1 suggesting a mechanism of resistance.

In an effort to increase the efficacy of vaccines, treatment with Poly-ICLC, which is a TLR3 and MDA5 agonist, along with Montanide, an oil-based vaccine adjuvant, and a NY-ESO-1 vaccine increased immunogenicity of the vaccine in patients with melanoma. This combination induced CD4+ and CD8+ T cells that were able to produce interferon (IFN)α, IFNγ, and interleukin (IL)-2. While this was not studied in patients with SS, the high level of NY-ESO-1 in SS makes this an ideal population for this approach.
responded with one patient having a complete response. The median OS was 120 weeks. Importantly this study documented that the maximal antitumor response in four patients occurred 3 months after starting therapy. This showed that there is a continued immune mediated response against the tumor mediated by in vivo expansion and persistence of the NY-ESO-1 cells after infusion. Other TCR’s, such as TBI-1301, are in clinical development and may have evidence of clinical benefit based on publicly presented data. In addition to a reduction in tumor size, infusion of both of these cell products led to cytokine release syndrome, as is often seen with effective cell-based therapeutics.

Larger scale clinical trials with these other cell products are eagerly awaited.

T-cells targeting MAGE-A4 have also made it to the clinic in larger scale clinical trials for patients with SS. There are currently three clinical trials involving T cells targeting MAGE-A4 involving patients with SS that are ongoing (NCT03132992, NCT04044768, NCT04044859). These studies use ADP-A2M4 which is a T-cell targeting MAGE-A4 peptide GYVDGREHTV. Promising in vitro and in vivo efficacy was seen in a mouse model. In the clinic, an initial report demonstrated clinical activity; 25% (7) of the patients had a PR. All seven of the patients who had a response had SS. Longer-term follow-up of patients with SS specifically demonstrated a response rate of 44%, with durable responses lasting at least 6 months. Preliminary translational analysis showed that MAGE-A4 expression levels and the total cell infusion dose correlated with response. Also within the MAGE family, a TCR targeting MAGE-A3 had clinical efficacy in one patient with SS enrolled on a larger multi-histology trial; but neurotoxicity thought to be secondary to cross reactivity with MAGE-A12 may limit further clinical development with this CTA as a target.

TCR editing using the CRISPR-Cas9 system may allow for optimization of the autologous T-cells to maximize the likelihood of a sustained antitumor response after cell infusion. The use of CRISPR engineered T cells against sarcoma has so far been limited, with the results of one phase I trial showing tumor evasion. These CRISPR engineered T cells, modified to express an NY-ESO-1 TCR and removal of the gene encoding PD-I, demonstrated long persistence for up to 9 months with no significant toxicity. There was also only one patient with sarcoma in this phase I trial, but this patient experienced the longest duration of SD observed. Additional advances such as the ability to reduce off-target editing by Cas9 and increase the specificity of gene targeting may ultimately lead to improvements in TCR development and production.

A major challenge of TCR therapies is the restriction of these modified T-cells to target patients who are HLA A*02:01 positive. HLA A*02:01 has the highest incidence within the USA in Caucasian populations with lower expression levels observed in Asian and African-American populations. This restriction limits the population that could possibly receive this treatment and leaves many other patients with little help beyond conventional methods, leaving a large unmet need for patients with other HLA haplotypes. They also require significant time for cell processing which can take on average 1–2 months to modify and grow the T cells before they are ready to be used.

Role of conditioning regimen in T-cell therapies

Although the TCR is the main active anti-sarcoma entity in adoptive T-cell therapy, the studies of NY-ESO-1 targeted T-cells highlighted the important role of the conditioning regimen for T-cell activity. Lymphodepleting immunomodulating drugs, such as fludarabine and cyclophosphamide, are used to deplete pre-existing lymphocytes that can compete with the transferred T cells. This lymphodepletion eliminates CD4+CD25+ regulatory lymphocytes and competition for endogenous cytokines and gives the transferred T cells an advantage to survive and populate in the host bone marrow. This process of depletion is done prior to treatment and increases the efficacy and numbers of lymphocytes in the tumor microenvironment (TME) after cell infusion. Fludarabine specifically has been shown to have the greatest effect on the T cell cytokines IL-7 and IL-15. An expansion study of the NY-ESO-1 cells sought to assess the activity of these cells in patients with lower expression level of NY-ESO-1 or with alternative pre-treatment lymphodepleting chemotherapy regimens. This resulted in fewer responses when comparing the expansion cohorts to the previous trial with higher intensity conditioning including fludarabine; with the initial trial having a response rate of 50% and the expansion cohorts having a combined response rate of 30%. These expansion cohorts demonstrated that more aggressive lymphodepletion may increase the likelihood for the success of TCR therapies and highlight the importance of fludarabine, which would otherwise not be used to treat SS. The intensive conditioning that patients must go through before receiving T-cells limits the patient population to those with good performance status. Older patients or those who have received multiple highly myelosuppressive regimens may have less bone marrow reserve and be less likely to tolerate the more effective higher intensity regimens, with fatal aplastic anemia reported in early studies.

SS MICROENVIRONMENT

CTA-targeted therapies such as vaccines and cell-based therapies are reliant on a favorable TME to exert their intended antitumor effects. The microenvironment consists of factors both intrinsic to the cancer cell such as secretion of immune modulating cytokines and expression of immune checkpoint inhibitors, and extrinsic such
as lymphocytes and macrophages, all of which interact with each other and create a microenvironment that can be immunogenic or ‘cold’. Immunologically ‘cold’ tumors are felt to be less suited for checkpoint inhibitors. Tumors with a high tumor mutation burden (TMB) tend to be more immunogenic. SS is an immunologically ‘cold’ tumor with a low TMB—a problem that must be overcome to maximize the benefit of CTA-targeted therapies.

SS has a low level of tumor infiltrating T cells (TIL). While in some inflammatory tumors like melanoma TIL are a marker for better prognosis, there is evidence suggesting that higher levels of CD8+ lymphocytes in the TME of SS might lead to worse metastasis free survival. Wedekind, et al. in particular found that recurrent or metastatic tumors were less likely to have high TIL infiltration, suggesting that the tumor may acquire changes allowing it to evade the immune system. One potential clinical consequence of this finding is that immune modulating treatment earlier in the patient’s course of disease might be of greater benefit than waiting for recurrence. PD-L1, PD-1, and CD8+ T cells are enriched at the perimeter of SS tumor, but relatively low inside the tumor. NY-ESO-1 expression levels are not correlated to CD8+ lymphocyte density in the tumor, indicating that the presence of CTAs in the tumor cells are not enough to stimulate endogenous cytotoxic T-cells into the tumor.

HLA expression in the tumor is crucial for the functioning and efficacy of adoptive T cells to recognize their antigen target and attack the tumor. SS generally has low HLA expression. Biphasic SS has higher HLA I expression in the epithelioid components compared with monophasic SS; 5 out of 10 patients had focal high expression in biphasic tumors compared with 1 out of 16 patients with monophasic SS. The overall deficiency of HLA I in SS has led to the idea that this might be a main mechanism by which SS is able to evade the immune system from either its own in vivo stimulation or via ex vivo therapeutics. Giving IFNγ in patients with SS has been shown to increase the levels of HLA I expression in the tumor cells along with increasing the density of TIL.

A phase 0 trial in patients with SS and myxoid/round cell liposarcoma (MRCL) designed to test whether IFNγ could increase MHC expression and T cell infiltration found that it did. Based on these results IFNγ was combined with NY-ESO-1 specific T cell therapy in a clinical trial but had a fatal complication. Subsequently, a multicenter trial combining IFNγ with PD-1 inhibition has been completed and data analysis is ongoing (NCT03063632).

There is some evidence that an immune reaction to CTAs can be instigated following treatment with checkpoint inhibitors. The presence and density of PD-1 and PD-L1 are correlated with a poorer prognosis for SS. While PD-L1 has been shown to be expressed in some SS tumors, the expression levels are typically low. PD-L1 is more highly expressed in metastatic or recurrent SS and its expression correlates with a shorter PFS. In a small clinical trial of ipilimumab in patients with advanced SS, there were hints of an immune response against MAGE-A3 and MAGE-A4 in response to checkpoint inhibition. This patient had detectable antibodies against these antigens prior to treatment, suggesting that immune checkpoint blockade may heighten pre-existing immune reactions against CTAs. Interestingly, this patient also had a seroconversion with newly detectable antibodies against CSAG2, another CTA, after treatment with ipilimumab. One patient (of 10 total with SS) responded to pembrolizumab on the SARC28 study. The low number of patients with SS in these studies demonstrating clear clinical benefit suggests that immune checkpoint inhibition alone is not sufficient to elicit clinically meaningful immune responses against CTAs.

SS is angiogenic with a predilection for formation of abnormal tumor vasculature. Dysregulated angiogenesis impedes immune cell trafficking, and co-administration of anti-angiogenic drugs with immune checkpoint inhibitors has been promising in preclinical models and in the clinic in other cancer types. The multi-kinase inhibitor with potent vascular endothelial growth factor receptor 2 (VEGFR2) inhibition pazopanib is a Food and Drug Administration approved drug with activity in SS. Combinations of anti-angiogenic agents with immune-based therapies may represent a mechanism to enhance immune responses against CTAs.

**FUTURE DIRECTIONS**

As more data demonstrating activity of CTA-targeted vaccines and TCR-based therapies emerges, additional efforts are underway to enhance the efficacy of these therapies and to develop additional ways of targeting CTAs.

CAR-T cells have also been used in various trials as experimental treatments to target CTA positive cancers. A major disadvantage of CAR-T cells is that they are limited to antigens that are expressed on the cell surface. While this can greatly limit the amount and type of antigens that these cells can target, CAR-T cells have been shown to elicit a greater release of cytokines, such as IL-2, CAR-T cells targeted against NY-ESO-1 have shown early efficacy in an in vivo murine model of NY-ESO-1 positive multiple myeloma. This study also included a NY-ESO-1 vaccine that was used to increase the efficacy and persistence of the CAR-T Cells. Given the preliminary success of autologous T-cells targeting NY-ESO-1 in patients with SS, additional study with CAR-T for NY-ESO-1 expressing SS is warranted and may allow a mechanism to overcome the HLA restriction that limits the applicability of autologous T-cell products.

Rational combinations of TCR-targeted therapies with other agents to modulate the immune microenvironment will be one focus of future research. Use of the cytokine IL-2, which promotes activation and cell growth of the transferred T lymphocytes, in conjunction with T cell therapy shows promise with positive responses by response evaluation criteria in solid tumors (RECIST) criteria in some patients. The use of checkpoint inhibitors has
also been proposed for concurrent use with other T cell or vaccine-based therapies.\textsuperscript{85} SS has low expression of checkpoint markers such as PD-1 and PD-L1, but the use of checkpoint inhibitors might aid in T cell or vaccine therapy, especially those who are recurrent or are metastatic.\textsuperscript{85, 89, 95}

Separate from vaccines and cell-based therapies, bispecific TCRs may also present a mechanism to effectively target CTAs without the time constraints that inherently come with vaccine or cell-based therapy. Bispecific TCRs are soluble molecules that are engineered to recognize their specific protein target and have an anti-CD3 base. Although there was one study of an anti-NY-ESO-1-anti-CD3 bispecific soluble TCR (NCT03515551), this molecule is no longer in clinical development.\textsuperscript{101}

Conclusions

CTAs are highly expressed in SS. Their limited expression in normal adult tissues presents an opportunity to target these aberrantly expressed proteins using various forms of immune mediated therapies. Indeed, significant progress has been made in developing CTA-targeted therapies for treatment of SS, in particular with HLA-restricted autologous T-cells targeting NY-ESO-1 and MAGE-A4. However, the inherent limitations of these therapies which are HLA restricted and require expression of the targeted CTA leave a large swath of patients without effective therapies. Additionally, intrinsic immune properties of SS and the sarcoma immune microenvironment allow some tumors to evade the immune system. To develop reliable CTA-targeted therapies that will be more broadly applicable and effective, future strategies will need to focus on rationally designed combinations that maximize the immune response against CTAs.

Twitter Seth M Pollack @immunosar and Michael J Wagner @wagsmd

Acknowledgements Figure 1 was created in Biorender.com.

Contributors All authors contributed to the writing of the original manuscript and reviewed the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests SMP receives research funding from Merck, EMD Serono, Incyte, Presage, Janssen, Oncoec and Juno. He has consulting, honoraria and advisory activity with GlaxoSmithKline, Apexigen, Daiichi Sankyo and T-Knife. MJW, advisory board for Deciphera, Adaptimmune, research support to institution from Adaptimmune, GSK, Athenex and Incyte. GM has no conflicts to declare.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Seth M Pollack http://orcid.org/0000-0002-2466-0607
Michael J Wagner http://orcid.org/0000-0002-0753-9282

REFERENCES

1. Deshmukh R, Mankin HJ, Singer S. Synovial sarcoma: the importance of size and location for survival. Clin Orthop Relat Res 2004;419:155–61.
2. Wang S, Song R, Sun T, et al. Survival changes in patients with synovial sarcoma, 2002–2012. J Cancer Res Clin Oncol 2015;141:1733–40.
3. Skytting B. Synovial sarcoma. A Scandinavian sarcoma group project. Acta Orthop Scand Suppl 2000;291:1–28.
4. Jones SF, Whitman RC. Primary sarcoma of the lower end of the femur involving the synovial membrane: with a critical review of the literature of synovial sarcoma report of one case with complete pathological and radiographic examination. Ann Surg 1914;60:440–50.
5. Barrott JJ, Illum BE, Jin H, et al. Paracrine osteoprotegerin and β-catenin stabilization support synovial sarcomagene expression in transgenic cells. J Clin Invest 2018;128:217–18.
6. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2000;36:81–7.
7. van der Graaf WTA, Blay J-Y, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879–86.
8. Kawai A, Araki N, Sugira H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, open-label, phase 2 study. Lancet Oncol 2015;16:406–16.
9. Pollack SM, Somiah NA, Araujo DM, et al. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/ring cell liposarcoma treated at major cancer centers in the United States. Cancer Med 2020;9:1244–51.
10. Tamaki S, Fukuta M, Sekiguchi K, et al. S18-Sx, the oncogenic fusion protein in synovial sarcoma, is a cellular context-dependent epigenetic modifier. PLoS One 2015;10:e0142991.
11. Middeljans E, Wan X, Jansen PW, et al. S18 together with animal-specific factors defines human BAF-type SWI/SNF complexes. PLoS One 2012;7:e33834.
12. Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012;21:333–47.
13. Nacev BA, Jones KB, Intlekofer AM. Witness to: the epigenomics of sarcoma. Nat Rev Cancer 2020;20:608–23.
14. McBride MJ, Pulice JL, Beird HC, et al. The SS18-SSX fusion oncprotein hijacks BAF complex targeting and function to drive synovial sarcoma. Cancer Cell 2018;33:1126–41.
15. Kazdoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013;153:71–85.
16. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983;157:1040–52.
17. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643–7.
18. Chen YT-T, Tran LT, Cohn MJ, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997;94:1914–8.
19. Chen YT, Güere AO, Tsang S, et al. Identification of multiple cancer/ testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A 1998;95:8919–23.
20. Almeida LG, Sakabe NJ, deOliveira AR, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009;37:D816–9.
21. Tammela J, Jungbluth AA, Gian F. SCP-1/cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelioid ovarian cancer. Cancer Immun 2004;4:10.
22. Ollinger R, Altheimer M, Benavente R. Mammalian protein SCP1 forms synaptonemal complex-like structures in the absence of meiotic chromosomes. Mol Biol Cell 2005;16:212–7.
23. Gjersostad MF, Kock K, Nielsen O, et al. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Human Reproduction 2007;22:953–60.
24. Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 2009;87:705–12.
25. De Smet C, De Backer O, Faraoni I, et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 1996;93:7149–53.
26. Simpson AJG, Caballero OL, Jungbluth A, et al. Cancer/ Testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615–25.
Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. *Int J Cancer* 2001;92:856–60.

28. Vaughan HA, Svobodova S, Macgregor D, et al. Immunohistological and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. *Clin Cancer Res* 2004;10:8396–40.

29. Grigoriadis A, Caballero OL, Hoek KS, et al. CT-X antigen expression in human breast cancer. *Proc Natl Acad Sci U S A* 2009;106:1309–14.

30. Yamada A, Kataoka A, Shichijo S, et al. Expression of MAGE-1, MAGE-2, MAGE-3/6 and MAGE-A4/4A genes in ovarian tumors. *Int J Cancer* 1995;64:388–93.

31. Kuratsugu T, Noguchi Y, Saika T, et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. *Cancer Res* 2001;61:4671–4.

32. Melloni G, Ferreri AJM, Russo V, et al. Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. *Oncol Rep* 2004;12:145–51.

33. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. *Clin Cancer Res* 2005;11:8055–62.

34. Taylor BJ, Reiman T, Pittman JA. Pilarski LM: SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. *J Immunother* 2005;28:564–75.

35. Chen CH, Huang GT, Lee HS, et al. High frequency of expression of MAGE genes in human hepatocellular carcinoma. *Liver* 1999;19:110–4.

36. Jäger E, Gnjatic S, Nagata Y, et al. Determinant of Morphology and Prognosis in Synovial Sarcoma. *J Immunother Cancer* 2020:25:5808–17.

37. Eso-1 c259. *J Immunother Cancer* 2019;7:296.

38. Vogt K, Harms B, Kneitz H, et al. Expression and clinical correlations of PRAME in sarcoma subtypes. *Journal of Clinical Oncology* 2016;34:3659–66.

39. Epping MT, Wang L, Edel MJ, et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. *Cell* 2005;123:85–97.

40. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. *Immunol Cell Biol* 1997;6:199–308.

41. D’Arcy P, Maruwhe W, Wolahan B, et al. Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells. *PLoS One* 2014;9:e85136.

42. Kawai A, Woodruff J, Healey JH, et al. SYT-SSX Gene Fusion as a Determinant of Morphology and Prognosis in Synovial Sarcoma. *N Engl J Med* 2008;358:135–60.

43. Somaiah N, Block MS, Kim JW, et al. First-In-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1. *Clin Cancer Res* 2019;25:5808–17.

44. Chawla S, Van Tine BA, Pollack S. A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: interim analysis of immunogenicity, tumor control and survival. *Ann Oncol* 2019;30:v523.

45. Somaiah N, Chawla SP, Block MS, et al. A phase 1B study evaluating the safety, tolerability, and immunogenicity of CMB305, a Lentinus-Based prime-boost vaccine regimen, in patients with locally advanced, relapsed, or metastatic cancer expressing NY-ESO-1. *Oncoimmunology* 2020;9:e134946.

46. Chawla SP, Van Tine BA, Pollack S, et al. A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: analysis of immunogenicity, tumor control, and patient survival. *J Clin Oncol* 2019;37:11011.

47. Ishihara M, Tono Y, Moriya Y, et al. First-In-Human phase I clinical trial of the NY-ESO-1 protein cancer vaccine candidate with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. *Cancer Immunol Immunother* 2020;69:663–75.

48. Kawaguchi S, Tsukahara T, Ida K, et al. Syt-Ssx breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese musculoskeletal Oncology Group. *Cancer Sci* 2012;103:1625–30.

49. Ebert LM, MacRaid SE, Zanker D, et al. Cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. *PLoS One* 2012;7:e48424.

50. Pavlick A, Blazquez AB, Meseck M, et al. Combined vaccination with NY-ESO-1 protein, Poly-ICCLC, and Montanide improves humoral and cellular immune responses in patients with high-risk melanoma. *Cancer Immunol Res* 2020;8:70–80.

51. Pollack SM, Jones EA, Farmer EA, et al. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells. *J Immunother Cancer* 2014;2:36.

52. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial sarcoma cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. *JCO* 2011;29:917–24.

53. Robbins PF, Li YF, El-Gamal M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. *J Immunol* 2008;180:6116–31.

54. Robbins PF, Kassim SH, Tran TLN, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell-receptor: long-term follow-up and correlates with response. *Clin Cancer Res* 2015;21:1019–27.

55. D’Angelo SP, Meliczior L, Merchant MS, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1∗259. *Cancer Discov* 2018;8:944–57.

56. Joseph J, Nathenson MJ, Trinh VA, et al. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. *J Immunother Cancer* 2019;7:236.

57. Butler MO, Sotov V, Sabisli S. Adaptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumor responses in patients with NY-ESO-1 expressing solid tumors. *Ann Oncol* 2019;30:302–9.

58. Hattori I, Ishihara M, Kitano S, et al. A novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumor responses in synovial sarcoma patients. *Ann Oncol* 2019;30:481.

59. Sandl C, Crowley DJ, Wiedermann GE, et al. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. *Oncoimmunology* 2020;9:1682381.
spear T cells in advanced solid tumors.

V. therapy and neurological toxicity following anti-

Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science2020;367:eaba7365.

Valuksas CA, Dever DP, Rettig GR, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med2018;24:1216–24.

Cao K, Hollenbach J, Shi X, et al. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol2001;62:1009–30.

Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol2008;26:5233–9.

Ramachandran I, Lowther DE, Dryer-Minnerly R, et al. Systemic and local immunity following adoptive transfer of NY-ESO-1 spear T cells in synovial sarcoma. J Immunother Cancer2019;7:276.

Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (time) for effective therapy. Nat Med2018;24:541–50.

He M, Abro B, Kaushal M, et al. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma. Hum Pathol2020;100:15–23.

Pollack SM, He Q, Yeeley JH, et al. T-Cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer2017;123:3291–304.

D’Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol2015;46:357–65.

Oike N, Kawashima H, Ogose A, et al. Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci2018;109:3043–54.

Wedekind MF, Haworth KB, Arnold M, et al. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatr Blood Cancer2018;65:e27313.

van Erp AEM, Versleijen-Jonkers YMH, Hillebrandt-Oudshoorn MHS, Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8. Oncotarget2017;8:71371–84.

Nowicki TS, Akiyama R, Huang RR, et al. Infiltration of CD8 T cells and expression of PD-1 and PD-L1 in synovial sarcoma. Cancer Immunol Res2017;5:118–26.

Zhang S, Cooper S, Donahue B, et al. Interferon gamma induced transformation of the cold tumor microenvironment in patients with NY-ESO-1 expressing sarcomas. Cancer Res2018;78.

Zhang S, Kohli K, Black RG, et al. Systemic interferon-γ increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial. Cancer Immunol Res2019;7:1237–43.

Schroeder BA, Black RG, Spadinger S, et al. Histioyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. J Immunother Cancer2020;8:e000247.

Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma2013;2013:168145.

Taiwbi HA, Burgess M, Boleajack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol2017;18:1493–501.

Barrott JJ, Kafchinski LA, Jin H, et al. Modeling synovial sarcoma metastasis in the mouse: PD-1 signaling and inflammation. J Exp Med2016;213:2989–3005.

Lee WS, Yang H, Chon HJ, et al. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med2020;52:1475–85.

Sroussi M, De Percin S, Grecea AM, et al. Pazopanib in advanced or metastatic synovial sarcoma: the Gustave Roussy experience. Annals of Oncology2018;29:viii589–90.

Harris DT, Kranz DM. Adoptive T cell therapies: a comparison of T cell receptor and chimeric antigen receptors. Trends Pharmacol Sci2016;37:220–30.

Lee WS, Maki RG, Jungbluth AA, et al. Pembrolizumab in advanced or metastatic synovial sarcoma: the Gustave Roussy experience. Annals of Oncology2018;29:viii589–90.

Harris DT, Hager MV, Smith SN, et al. Comparison of T cell activities mediated by human TCRs and cars that use the same recognition domains. JCI. 2018;200:1088–100.

Katel K, Olivares S, Singh J, et al. Combination immunotherapy with NY-ESO-1-specific CAR+ T cells with T-cell vaccine improves anti-myeloma effect. Blood2016;128:3366.

Lopez J, Shinde R, Burgess MA. Trial in progress: first-in-human study of a novel anti-NY-ESO-1--anti-CD3, TRC-based bispecific (IMC-my205) monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumours (IMCnyeso-101). Ann Oncol2019;30:v532.

Ayyoub M, Taub RN, Keohan M-L. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun2004;4:7.

Antonescu CR, Busam KJ, Iversen K, et al. Mage antigen expression in monophasic and biphasic synovial sarcoma. Hum Pathol2002;33:225–9.

Guilhou L, Coindre J, Gallagher G, et al. Detection of the synovial sarcoma translocation t(X;18) (SYT/SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Hum Pathol2001;32:105–12.

Wei Y, Wang J, Zhu X, et al. Detection of SYT-SSX fusion transcripts in paraffin-embedded tissues of synovial sarcoma by reverse transcription-polymerase chain reaction. Chin Med J2002;115:1043–7.